INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2008

High-dose intravenous ascorbic acid was safe but did not display objective anticancer activity.

In a phase I dose-finding study, patients with advanced cancer received infusions of ascorbic acid ranging from 0.4 to 1.5 g/kg three times weekly. Toxicity and adverse events were minimal across all dose groups. However, no participant showed an objective anticancer response.

Study type
Phase I non-randomized clinical trial
Who was studied
Patients with advanced cancer or hematologic malignancy
What was measured
Adverse events, toxicity, and objective anticancer response

THE PAPER

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.

Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Ann Oncol, 2008.

PubMed 18544557 ↗DOI 10.1093/annonc/mdn377 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.